Search News Releases

Americans’ use of common outpatient health services dipped sharply at the outset of the COVID-19 pandemic, then rebounded to near-normal levels by the end of 2020, only to decline again during the second surge in January–February 2021. But the 2020 recovery in care wasn’t equal for all, researchers found. Some of the most socioeconomically disadvantaged patients — those with Medicaid or Medicare-Medicaid dual eligibility insurance — were far less likely than those with other insurance plans to return to using outpatient services at rates approaching normal, pre-pandemic levels.

Researchers in a multi-institution study led by UCLA Health have identified several overlooked issues affecting women with Parkinson’s Disease (PD) and call for more research, customized treatments, education and support to empower women living with this disease and to address their unmet medical needs.

The UCLA Center for SMART Health, an interdisciplinary collaborative that looks to the integrated transformation of healthcare through emergent data and technologies, and Hearst Health, a division of Hearst and leader in care guidance, today announced their partnership to offer the Hearst Health Prize.

Results of a large study led by UCLA Jonsson Comprehensive Cancer Center researchers could help guide treatment planning for patients with high-risk prostate cancer.

A new study led by researchers at UCLA Health finds no evidence of SARS-CoV-2 transmission through breastmilk.

A new meta-analysis of randomized, controlled clinical trials provides strong support for adding androgen deprivation therapy (ADT) to definitive radiotherapy (RT) for the treatment of prostate cancer, projecting that doing so would prevent one cancer from metastasizing for every 10 to 15 men treated.

Researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used prostate cancer patients’ DNA to create a model that appears to predict who will have side effects from radiation. 

A new study finds that while young and healthy mice show clear differences between daytime and nighttime body temperature rhythms, in older and diseased animals the difference essentially disappeared.

A study in mice led by UCLA researchers shows that removing chemical messengers in the brain that are involved in both wakefulness and addiction may make withdrawal from opioids easier and help prevent relapse.

Research led by scientists at the Jonsson Comprehensive Cancer Center (JCCC) at UCLA provides new insights into molecular “crosstalk” in pancreas cancer cells, identifying vulnerabilities that could provide a target for therapeutic drugs already being studied in several cancers.

In a study using mice, a UCLA-led team of researchers have improved upon a method they developed in 2017 that was designed to kill HIV-infected cells. The advance could move scientists a step closer to being able to reduce the amount of virus, or even eliminate it, from infected people who are dependent on lifesaving medications to keep the virus from multiplying and illness at bay.

New UCLA-led research in mice suggests that adding a certain type of tomato concentrate to the diet can reduce the intestinal inflammation that is associated with HIV. Left untreated, intestinal inflammation can accelerate arterial disease, which in turn can lead to heart attack and stroke.

Dr. Andrei Gafita,  a postdoctoral scholar in the Ahmanson Translational Theranostics Division at UCLA and the UCLA Jonsson Comprehensive Cancer Center, has been named a recipient of a 2021 Young Investigator Award by the Prostate Cancer Foundation.

UCLA Jonsson Comprehensive Cancer Center researcher Amar Kishan, MD, has received a $1.15 million grant from the Department of Defense (DoD) to spearhead a project that explores important basic science concepts in the treatment of prostate cancer: evaluating and optimizing the physics of radiation delivery and dissecting the biology of the tumoral response to radiation.

UCLA Jonsson Comprehensive Cancer Center researchers leading a meta-analysis of seven randomized trials found an “unexpected result”: Although Black men appeared to have more aggressive disease when they enrolled in clinical trials of radiation therapy for prostate cancer, their treatment outcomes and disease-specific outcomes were better than those of their white counterparts.

Precision therapies targeting melanoma and other cancers have improved patient survival, but tumors often stop responding to drugs, and recent studies point to changes in DNA – both inside and outside chromosomes – as a driving factor in tumor genesis as well as in treatment resistance.

Researchers at UCLA Jonsson Comprehensive Cancer Center led a large international study providing what is believed to be the first evidence that a recently approved imaging technique improves risk-stratification and long-term prognostic capabilities for patients with high-risk prostate cancer.

A subgroup analysis of a phase III study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found consistent progression-free survival (PFS) and objective response rate (ORR) benefit when women with HER2-positive metastatic breast cancer were treated with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd), compared to the current standard of treatment.